Skip to content
Search

Latest Stories

Covid-19 booster vaccine programme to begin next week

The UK government today (September 14) announced the nine groups that are most vulnerable to Covid-19 will be eligible for a third booster dose of vaccine, six months after their second dose.

Health and Social Care secretary Sajid Javid told the Commons that the government has accepted the advice of the Joint Committee on Vaccination and Immunisation (JCVI) on booster jabs, and the NHS is preparing to offer Covid booster vaccine from next week.


Under the booster programme around 30 million people are likely to be offered a third dose.

More than 112,000 lives were saved and 24 million cases were averted because of Covid-19 vaccines, British officials said while recommending a booster shot for all vulnerable people, earlier today.

In its recommendation to the government, the JCVI has given preference to the Pfizer-BioNTech vaccine for the booster programme or alternatively a half-dose of a Moderna shot.

The committee has advised administering booster jab to those living in residential care homes for older adults, adults aged 50 years or over, frontline health and social care workers, adult contacts of immunosuppressed individuals and all those aged 16 to 49 years with serious health condition.

The advice comes ahead of an announcement by the government on its strategy for taming infections during this winter.

Professor Wei Shen Lim, chair of Covid-19 immunisation for the JCVI, said, “the main aim of the booster programme is to prolong that protection and reduce serious disease as we head towards the colder months.

“The JCVI is advising that a booster dose be offered to the more vulnerable, to maximise individual protection ahead of an unpredictable winter. Most of these people will also be eligible for the annual flu vaccine and we strongly advise them to take up this offer as well.”

Commenting on the Covid-19 vaccination booster programme announcement, Ruth Rankine, director of primary care at the NHS Confederation, said: “Our members will welcome confirmation of this final decision following weeks of uncertainty about the plans. Primary care has played a crucial part in the highly successful roll out of the vaccination programme to date and will continue to deliver to protect their patients and the public.”

She, however, noted that delivering booster programme along with the government’s recent decision to vaccinate 12–15-year-olds will require more time and investment.

She said: “we must also acknowledge the amount of time and investment that will be needed to deliver both these programmes alongside the flu vaccination programme, set against what is already an extremely busy time with primary care seeing a huge increase in demand coupled with increasingly complex cases, and managing patients waiting for secondary care treatment.”

More For You

Pharmacist handing medicine to patient, NHS prescription cost freeze debate

Prescription charge will remain at £9.90

Pic credit: iStock

NPA calls for end to prescription charge after freeze announcement

The National Pharmacy Association (NPA) has asked for prescription charges to be completely removed despite the government announcing today that the charge will be frozen for the first time in three years.

Patients will continue paying £9.90 to collect their medication from a pharmacy.

Keep ReadingShow less
RPS launches new prescribing development programme for pharmacists

From 2026, every newly qualified pharmacist will be an independent prescriber

gettyimages

RPS unveils new training programme to enhance pharmacists’ prescribing skills

The Royal Pharmaceutical Society (RPS) has announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

The initiative comes ahead of the NHS mandate that every newly qualified pharmacist will be an independent prescriber by 2026 — a change set to transform the future of pharmacy practice.

Keep ReadingShow less
Varenicline promotes nicotine vaping cessation in young people

Researchers warn that e-cigarette use can increase risk for nicotine addiction,uptake of combusted tobacco and other substance use.

gettyimages

Anti-smoking pill varenicline may help young people quit vaping, new study suggests

Varenicline — a daily pill already offered through NHS Stop Smoking Services — could also support young people in quitting vaping, new research has suggested.

The medication, proven to be more effective than nicotine replacement gums or patches for smoking cessation, was shown to significantly boost vaping abstinence when combined with behavioural counselling in adolescents and young adults.

Keep ReadingShow less
Relying on blue inhalers alone can worsen asthma symptoms, warns MHRA

Patients are advised to use their preventer inhaler regularly, even if their asthma feels under control.

Pic credit: gettyimages

Overuse of blue inhalers can increase risk of severe asthma attacks, warns MHRA

The Medicines and Healthcare products Regulatory Agency (MHRA) is reminding asthma patients to use their preventer (anti-inflammatory) inhalers regularly as prescribed, rather than relying solely on their blue inhalers, also referred to as reliever inhalers.

“Without regular use of a preventer inhaler, symptoms could worsen and increase the risk of severe asthma attacks,” the MHRA warned.

Keep ReadingShow less
13 pharmacists achieve RPS core advanced credential with record pass rate

The latest successful cohort includes pharmacists from both England and Scotland.

Pic credit: Getty Images

13 more pharmacists achieve RPS core advanced credential - Highest pass rate yet

The Royal Pharmaceutical Society (RPS) has announced that 13 more pharmacists have successfully completed Core Advanced Credentialling as part of the latest assessment cohort —achieving a remarkable 93% pass rate, the highest to date.

This brings the total number of pharmacists awarded the RPS core advanced credential to 113 since the launch of the Core Advanced Curriculum in 2023, with successful candidates from GP, secondary care and community settings.

Keep ReadingShow less